Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Immunotherapy for Hematological and Solid Cancers
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Immunotherapy for Hematological and Solid Cancers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 13635

Special Issue Editor

Dr. Pascal Gélébart

E-Mail Website
Guest Editor
Universitetet i Bergen, Bergen, Norway
Interests: CAR T cell; TiLS; Adaptive immunology; Immunotherapy; Animal models; Pre clinical drug evaluation

Special Issue Information

Dear colleague,

The objective of this special issue will be to provide to an overview of the latest developments in the field of immunotherapy for 1) hematological malignancies and 2) various form of solid cancers. This will encompass the field of drug-based immunotherapy (i.e., checkpoint inhibitors) and immune cell-based therapy with a focus on Chimeric Antigen Receptor therapy (i.e., CAR T, CAR NK), dendritic cell therapy, as well as Tumor infiltrated lymphocytes (TiLs).

The special issue will explore the latest innovation in CAR molecular design performed to improve the specific targeting of cancer cells and the effort done to address the major weakness of the technology (i.e., T-cell exhaustion, tumor accessibility).

Dr. Pascal Gélébart
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • checkpoint inhibitors
  • chimeric antigen receptor therapy (CAR T) cell for hematological and solid cancers
  • T cell receptor CAR (TCR CAR)
  • dendritic cell therapy
  • tumor-infiltrated lymphocytes (TiLs)

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2222 KiB  
Article
Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti–PD-1 Treatment Efficacy in Urothelial Carcinoma
by Hiroshi Fukushima, Soichiro Yoshida, Toshiki Kijima, Yuki Nakamura, Shohei Fukuda, Sho Uehara, Yosuke Yasuda, Hajime Tanaka, Minato Yokoyama, Yoh Matsuoka and Yasuhisa Fujii
Int. J. Mol. Sci. 2021, 22(2), 535; https://doi.org/10.3390/ijms22020535 - 7 Jan 2021
Cited by 20 | Viewed by 3482
Abstract
The therapeutic benefit of immune checkpoint inhibitor monotherapy is limited to a subset of patients in urothelial carcinoma (UC). Previous studies showed the immunogenicity of cisplatin and irradiation. Here, we investigated whether chemoradiotherapy (CRT), a combination of cisplatin and irradiation, could improve the [...] Read more.
The therapeutic benefit of immune checkpoint inhibitor monotherapy is limited to a subset of patients in urothelial carcinoma (UC). Previous studies showed the immunogenicity of cisplatin and irradiation. Here, we investigated whether chemoradiotherapy (CRT), a combination of cisplatin and irradiation, could improve the efficacy of postirradiation anti–programmed cell death 1 (PD-1) treatment in UC. In our advanced UC patient cohort, patients with CRT showed a significantly better objective response rate (75%/22%) and overall survival (88%/30% at 12 months) following later pembrolizumab therapy compared to those without. Then, we created syngeneic UC mouse models by inoculating MB49 cells s.c. in C57BL/6J mice to examine the potential of CRT to enhance antitumor immunity in conjunction with postirradiation anti–PD-1 treatment. Nonirradiated tumors of the mice treated with CRT/postirradiation anti–PD-1 treatment had a significantly slower growth rate and a significantly higher expression of cytotoxic T cells compared to those of the mice treated with anti–PD-1 treatment alone. The mice treated with CRT/postirradiation anti–PD-1 treatment showed the best survival. Mechanistically, CRT provoked strong direct cytotoxicity and increased expressions of immunogenic cell death markers in MB49 cells. Therefore, the combination of cisplatin and irradiation induces immunogenic cell death and potentiates postirradiation anti–PD-1 treatment efficacy in UC. Full article
(This article belongs to the Special Issue Immunotherapy for Hematological and Solid Cancers)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

23 pages, 2720 KiB  
Review
Pharmacologic Control of CAR T Cells
by Benjamin Caulier, Jorrit M. Enserink and Sébastien Wälchli
Int. J. Mol. Sci. 2021, 22(9), 4320; https://doi.org/10.3390/ijms22094320 - 21 Apr 2021
Cited by 9 | Viewed by 5351
Abstract
Chimeric antigen receptor (CAR) therapy is a promising modality for the treatment of advanced cancers that are otherwise incurable. During the last decade, different centers worldwide have tested the anti-CD19 CAR T cells and shown clinical benefits in the treatment of B cell [...] Read more.
Chimeric antigen receptor (CAR) therapy is a promising modality for the treatment of advanced cancers that are otherwise incurable. During the last decade, different centers worldwide have tested the anti-CD19 CAR T cells and shown clinical benefits in the treatment of B cell tumors. However, despite these encouraging results, CAR treatment has also been found to lead to serious side effects and capricious response profiles in patients. In addition, the CD19 CAR success has been difficult to reproduce for other types of malignancy. The appearance of resistant tumor variants, the lack of antigen specificity, and the occurrence of severe adverse effects due to over-stimulation of the therapeutic cells have been identified as the major impediments. This has motivated a growing interest in developing strategies to overcome these hurdles through CAR control. Among them, the combination of small molecules and approved drugs with CAR T cells has been investigated. These have been exploited to induce a synergistic anti-cancer effect but also to control the presence of the CAR T cells or tune the therapeutic activity. In the present review, we discuss opportunistic and rational approaches involving drugs featuring anti-cancer efficacy and CAR-adjustable effect. Full article
(This article belongs to the Special Issue Immunotherapy for Hematological and Solid Cancers)
►▼ Show Figures

Figure 1

23 pages, 2104 KiB  
Review
The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies
by Giovanni Zarrilli, Gianluca Businello, Maria Vittoria Dieci, Silvia Paccagnella, Valentina Carraro, Rocco Cappellesso, Federica Miglietta, Gaia Griguolo, Valentina Guarneri, Marcello Lo Mele and Matteo Fassan
Int. J. Mol. Sci. 2020, 21(21), 8102; https://doi.org/10.3390/ijms21218102 - 30 Oct 2020
Cited by 26 | Viewed by 4165
Abstract
Breast cancer evolves thanks to a dense and close interaction with the surrounding tumor microenvironment (TME). Fibroblasts, leukocytes, blood and lymphatic endothelial cells and extracellular matrix are the constituents of this entity, and they synergistically play a pivotal role in all of the [...] Read more.
Breast cancer evolves thanks to a dense and close interaction with the surrounding tumor microenvironment (TME). Fibroblasts, leukocytes, blood and lymphatic endothelial cells and extracellular matrix are the constituents of this entity, and they synergistically play a pivotal role in all of the stages of breast cancer development, from its onset to its metastatic spread. Moreover, it has been widely demonstrated that variations to the TME can correspond to prognosis variations. Breast cancer not only modulates the transformation of the environment within the mammary gland, but the same process is observed in metastases as well. In this minireview, we describe the features of TME within the primitive breast cancer, throughout its evolution and spread into the main metastatic sites. Full article
(This article belongs to the Special Issue Immunotherapy for Hematological and Solid Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop